O	0	12	Angiogenesis	Angiogenesis	NN	B-NP
O	12	13	-	-	:	O
O	13	14	a	a	DT	B-NP
O	15	20	novel	novel	JJ	I-NP
O	21	32	therapeutic	therapeutic	JJ	I-NP
O	33	41	approach	approach	NN	I-NP
O	42	45	for	for	IN	B-PP
O	46	54	ischemic	ischemic	JJ	B-NP
B-Organ	55	60	heart	heart	NN	I-NP
O	61	68	disease	disease	NN	I-NP
O	68	69	.	.	.	O

O	70	82	Angiogenesis	Angiogenesis	NN	B-NP
O	83	85	is	be	VBZ	B-VP
O	86	89	the	the	DT	B-NP
O	90	98	biologic	biologic	JJ	I-NP
O	99	106	process	process	NN	I-NP
O	107	109	of	of	IN	B-PP
O	110	117	forming	form	VBG	B-VP
O	118	121	new	new	JJ	B-NP
B-Multi-tissue_structure	122	127	blood	blood	NN	I-NP
I-Multi-tissue_structure	128	135	vessels	vessel	NNS	I-NP
O	135	136	.	.	.	O

O	137	148	Undoubtedly	Undoubtedly	RB	B-ADVP
O	148	149	,	,	,	O
B-Multi-tissue_structure	150	155	blood	blood	NN	B-NP
I-Multi-tissue_structure	156	163	vessels	vessel	NNS	I-NP
O	164	170	growth	growth	NN	I-NP
O	171	181	regulation	regulation	NN	I-NP
O	182	184	is	be	VBZ	B-VP
O	185	186	a	a	DT	B-NP
O	187	192	vital	vital	JJ	I-NP
O	193	199	aspect	aspect	NN	I-NP
O	200	202	in	in	IN	B-PP
O	203	209	health	health	NN	B-NP
O	210	213	and	and	CC	I-NP
O	214	221	disease	disease	NN	I-NP
O	221	222	.	.	.	O

O	223	228	Under	Under	IN	B-PP
O	229	242	physiological	physiological	JJ	B-NP
O	243	253	conditions	condition	NNS	I-NP
O	253	254	,	,	,	O
O	255	267	angiogenesis	angiogenesis	NN	B-NP
O	268	270	is	be	VBZ	B-VP
O	271	280	regulated	regulate	VBN	I-VP
O	281	283	by	by	IN	B-PP
O	284	289	local	local	JJ	B-NP
O	290	297	balance	balance	NN	I-NP
O	298	305	between	between	IN	B-PP
O	306	316	endogenous	endogenous	JJ	B-NP
O	317	328	stimulators	stimulator	NNS	I-NP
O	329	332	and	and	CC	I-NP
O	333	343	inhibitors	inhibitor	NNS	I-NP
O	344	346	of	of	IN	B-PP
O	347	351	this	this	DT	B-NP
O	352	359	process	process	NN	I-NP
O	359	360	.	.	.	O

O	361	363	In	In	IN	B-PP
O	364	368	many	many	JJ	B-NP
O	369	377	diseases	disease	NNS	I-NP
O	378	383	state	state	NN	I-NP
B-Organism_subdivision	384	388	body	body	NN	I-NP
O	389	394	loses	lose	VBZ	B-VP
O	395	402	control	control	NN	B-NP
O	403	407	over	over	IN	B-PP
O	408	420	angiogenesis	angiogenesis	NN	B-NP
O	420	421	.	.	.	O

O	422	434	Angiogenesis	Angiogenesis	NN	B-NP
O	434	435	-	-	HYPH	I-NP
O	435	444	dependent	dependent	JJ	I-NP
O	445	453	diseases	disease	NNS	I-NP
O	454	460	result	result	VBP	B-VP
O	461	465	when	when	WRB	B-ADVP
O	466	469	new	new	JJ	B-NP
B-Multi-tissue_structure	470	475	blood	blood	NN	I-NP
I-Multi-tissue_structure	476	483	vessels	vessel	NNS	I-NP
O	484	490	either	either	CC	O
O	491	495	grow	grow	VB	B-VP
O	496	507	excessively	excessively	RB	B-ADVP
O	508	510	or	or	CC	I-ADVP
O	511	525	insufficiently	insufficiently	RB	I-ADVP
O	525	526	.	.	.	O

O	527	539	Insufficient	Insufficient	JJ	B-NP
O	540	552	angiogenesis	angiogenesis	NN	I-NP
O	553	559	occurs	occur	VBZ	B-VP
O	560	562	in	in	IN	B-PP
O	563	571	diseases	disease	NNS	B-NP
O	572	576	such	such	JJ	B-PP
O	577	579	as	as	IN	I-PP
B-Multi-tissue_structure	580	588	coronary	coronary	JJ	B-NP
I-Multi-tissue_structure	589	595	artery	artery	NN	I-NP
O	596	603	disease	disease	NN	I-NP
O	603	604	,	,	,	O
O	605	611	stroke	stroke	NN	B-NP
O	612	615	and	and	CC	O
O	616	623	chronic	chronic	JJ	B-NP
B-Pathological_formation	624	630	wounds	wound	NNS	I-NP
O	630	631	.	.	.	O

B-Multi-tissue_structure	632	642	Myocardial	Myocardial	JJ	B-NP
O	643	651	ischemia	ischemia	NN	I-NP
O	652	656	both	both	CC	O
O	657	662	acute	acute	JJ	B-ADJP
O	663	666	and	and	CC	I-ADJP
O	667	674	chronic	chronic	JJ	I-ADJP
O	675	678	has	have	VBZ	B-VP
O	679	683	been	be	VBN	I-VP
O	684	691	clearly	clearly	RB	I-VP
O	692	697	shown	show	VBN	I-VP
O	698	700	to	to	TO	I-VP
O	701	710	stimulate	stimulate	VB	I-VP
O	711	723	angiogenesis	angiogenesis	NN	B-NP
O	724	726	in	in	IN	B-PP
O	727	731	many	many	JJ	B-NP
O	732	744	experimental	experimental	JJ	I-NP
O	745	751	models	model	NNS	I-NP
O	751	752	.	.	.	O

O	753	764	Therapeutic	Therapeutic	JJ	B-NP
O	765	777	angiogenesis	angiogenesis	NN	I-NP
O	778	780	is	be	VBZ	B-VP
O	781	784	the	the	DT	B-NP
O	785	795	biological	biological	JJ	I-NP
O	796	802	agents	agent	NNS	I-NP
O	803	805	or	or	CC	O
O	806	815	bioactive	bioactive	JJ	B-NP
O	816	824	material	material	NN	I-NP
O	825	827	to	to	TO	B-VP
O	828	837	stimulate	stimulate	VB	I-VP
O	838	841	the	the	DT	B-NP
O	842	848	growth	growth	NN	I-NP
O	849	851	of	of	IN	B-PP
O	852	855	new	new	JJ	B-NP
B-Multi-tissue_structure	856	861	blood	blood	NN	I-NP
I-Multi-tissue_structure	862	869	vessels	vessel	NNS	I-NP
O	869	870	.	.	.	O

O	871	882	Traditional	Traditional	JJ	B-NP
B-Multi-tissue_structure	883	891	coronary	coronary	JJ	I-NP
O	892	909	revascularization	revascularization	NN	I-NP
O	910	919	therapies	therapy	NNS	I-NP
O	920	924	such	such	JJ	B-PP
O	925	927	as	as	IN	I-PP
B-Multi-tissue_structure	928	936	coronary	coronary	JJ	B-NP
O	937	948	angioplasty	angioplasty	JJ	I-NP
O	949	951	or	or	CC	I-NP
B-Multi-tissue_structure	952	958	bypass	bypass	JJ	I-NP
I-Multi-tissue_structure	959	964	graft	graft	NN	I-NP
O	965	972	surgery	surgery	NN	I-NP
O	972	973	,	,	,	O
O	974	977	act	act	VBP	B-VP
O	978	980	by	by	IN	B-PP
O	981	990	restoring	restore	VBG	B-VP
B-Organism_substance	991	996	blood	blood	NN	B-NP
O	997	1001	flow	flow	NN	I-NP
O	1002	1009	through	through	IN	B-PP
O	1010	1013	the	the	DT	B-NP
O	1014	1025	preexisting	preexisting	JJ	I-NP
B-Multi-tissue_structure	1026	1034	coronary	coronary	JJ	I-NP
I-Multi-tissue_structure	1035	1042	vessels	vessel	NNS	I-NP
O	1042	1043	.	.	.	O

O	1044	1047	One	One	CD	B-NP
O	1048	1058	limitation	limitation	NN	I-NP
O	1059	1061	of	of	IN	B-PP
O	1062	1067	these	these	DT	B-NP
O	1068	1078	approaches	approach	NNS	I-NP
O	1078	1079	,	,	,	O
O	1080	1087	however	however	RB	B-ADVP
O	1087	1088	,	,	,	O
O	1089	1092	may	may	MD	B-VP
O	1093	1095	be	be	VB	I-VP
O	1096	1099	the	the	DT	B-NP
O	1100	1107	failure	failure	NN	I-NP
O	1108	1110	to	to	TO	B-VP
O	1111	1120	normalize	normalize	VB	I-VP
B-Multi-tissue_structure	1121	1131	myocardial	myocardial	JJ	B-NP
O	1132	1141	perfusion	perfusion	NN	I-NP
O	1141	1142	,	,	,	O
O	1143	1146	due	due	IN	B-PP
O	1147	1149	to	to	TO	B-PP
O	1150	1153	the	the	DT	B-NP
O	1154	1165	concomitant	concomitant	JJ	I-NP
O	1166	1174	presence	presence	NN	I-NP
O	1175	1177	or	or	CC	O
O	1178	1183	small	small	JJ	B-ADJP
O	1184	1186	of	of	IN	B-PP
O	1187	1197	resistance	resistance	NN	B-NP
B-Multi-tissue_structure	1198	1204	vessel	vessel	NN	I-NP
O	1205	1212	disease	disease	NN	I-NP
O	1212	1213	.	.	.	O

O	1214	1216	In	In	IN	B-PP
O	1217	1225	contrast	contrast	NN	B-NP
O	1225	1226	,	,	,	O
O	1227	1238	therapeutic	therapeutic	JJ	B-NP
O	1239	1251	angiogenesis	angiogenesis	NN	I-NP
O	1252	1254	is	be	VBZ	B-VP
O	1255	1260	based	base	VBN	I-VP
O	1261	1263	on	on	IN	B-PP
O	1264	1267	the	the	DT	B-NP
O	1268	1275	concept	concept	NN	I-NP
O	1276	1280	that	that	IN	B-SBAR
B-Multi-tissue_structure	1281	1289	coronary	coronary	JJ	B-NP
I-Multi-tissue_structure	1290	1300	collateral	collateral	JJ	I-NP
O	1301	1312	development	development	NN	I-NP
O	1313	1316	may	may	MD	B-VP
O	1317	1319	be	be	VB	I-VP
O	1320	1330	stimulated	stimulate	VBN	I-VP
O	1331	1333	by	by	IN	B-PP
O	1334	1349	pharmacological	pharmacological	JJ	B-NP
O	1350	1352	or	or	CC	I-NP
O	1353	1362	molecular	molecular	JJ	I-NP
O	1363	1368	means	mean	NNS	I-NP
O	1369	1372	and	and	CC	O
O	1373	1376	can	can	MD	B-VP
O	1377	1382	limit	limit	VB	I-VP
B-Multi-tissue_structure	1383	1393	myocardial	myocardial	JJ	B-NP
O	1394	1402	ischemia	ischemia	NN	I-NP
O	1402	1403	.	.	.	O

O	1404	1411	Studies	Study	NNS	B-NP
O	1411	1412	,	,	,	O
O	1413	1417	both	both	CC	O
O	1418	1420	in	in	IN	B-PP
O	1421	1426	human	human	JJ	B-NP
O	1427	1430	and	and	CC	I-NP
O	1431	1437	animal	animal	JJ	I-NP
O	1438	1444	models	model	NNS	I-NP
O	1445	1452	support	support	VBP	B-VP
O	1453	1456	the	the	DT	B-NP
O	1457	1463	notion	notion	NN	I-NP
O	1464	1468	that	that	IN	B-SBAR
O	1468	1469	,	,	,	O
O	1470	1477	various	various	JJ	B-NP
O	1478	1488	angiogenic	angiogenic	JJ	I-NP
O	1489	1495	growth	growth	NN	I-NP
O	1496	1503	factors	factor	NNS	I-NP
O	1504	1507	and	and	CC	O
B-Cell	1508	1518	progenitor	progenitor	NN	B-NP
I-Cell	1519	1524	cells	cell	NNS	I-NP
O	1525	1528	can	can	MD	B-VP
O	1529	1536	enhance	enhance	VB	I-VP
O	1537	1540	new	new	JJ	B-NP
B-Multi-tissue_structure	1541	1546	blood	blood	NN	I-NP
I-Multi-tissue_structure	1547	1554	vessels	vessel	NNS	I-NP
O	1554	1555	.	.	.	O

O	1556	1564	Vascular	Vascular	JJ	B-NP
O	1565	1576	endothelial	endothelial	JJ	I-NP
O	1577	1583	growth	growth	NN	I-NP
O	1584	1590	factor	factor	NN	I-NP
O	1591	1592	(	(	(	O
O	1592	1596	VEGF	VEGF	NN	B-NP
O	1596	1597	)	)	)	O
O	1597	1598	,	,	,	O
O	1599	1609	fibroblast	fibroblast	NN	B-NP
O	1610	1616	growth	growth	NN	I-NP
O	1617	1623	factor	factor	NN	I-NP
O	1624	1625	(	(	(	O
O	1625	1628	FGF	FGF	NN	B-NP
O	1628	1629	)	)	)	O
O	1629	1630	,	,	,	O
O	1631	1642	recombinant	recombinant	JJ	B-NP
O	1643	1651	proteins	protein	NNS	I-NP
O	1652	1655	and	and	CC	O
B-Cell	1656	1660	bone	bone	NN	B-NP
I-Cell	1661	1667	marrow	marrow	NN	I-NP
I-Cell	1668	1672	stem	stem	NN	I-NP
I-Cell	1673	1678	cells	cell	NNS	I-NP
O	1679	1682	are	be	VBP	B-VP
O	1683	1692	currently	currently	RB	I-VP
O	1693	1697	used	use	VBN	I-VP
O	1698	1709	therapeutic	therapeutic	JJ	B-NP
O	1710	1721	stimulators	stimulator	NNS	I-NP
O	1722	1725	for	for	IN	B-PP
O	1726	1738	angiogenesis	angiogenesis	NN	B-NP
O	1738	1739	.	.	.	O

O	1740	1742	As	As	IN	B-SBAR
B-Multi-tissue_structure	1743	1751	coronary	coronary	JJ	B-NP
I-Multi-tissue_structure	1752	1758	artery	artery	NN	I-NP
O	1759	1766	disease	disease	NN	I-NP
O	1767	1769	is	be	VBZ	B-VP
O	1770	1773	the	the	DT	B-NP
O	1774	1779	major	major	JJ	I-NP
O	1780	1785	cause	cause	NN	I-NP
O	1786	1788	of	of	IN	B-PP
O	1789	1794	death	death	NN	B-NP
O	1795	1797	in	in	IN	B-PP
O	1798	1801	the	the	DT	B-NP
O	1802	1811	developed	develop	VBN	I-NP
O	1812	1821	societies	society	NNS	I-NP
O	1822	1825	and	and	CC	O
O	1826	1830	also	also	RB	B-ADVP
O	1831	1833	an	an	DT	B-NP
O	1834	1842	emerging	emerge	VBG	I-NP
O	1843	1849	health	health	NN	I-NP
O	1850	1857	problem	problem	NN	I-NP
O	1858	1860	in	in	IN	B-PP
O	1861	1871	developing	develop	VBG	B-NP
O	1872	1881	countries	country	NNS	I-NP
O	1882	1886	like	like	IN	B-PP
O	1887	1897	Bangladesh	Bangladesh	NNP	B-NP
O	1898	1909	therapeutic	therapeutic	JJ	I-NP
O	1910	1922	angiogenesis	angiogenesis	NN	I-NP
O	1923	1926	may	may	MD	B-VP
O	1927	1934	provide	provide	VB	I-VP
O	1935	1939	hope	hope	NN	B-NP
O	1940	1942	as	as	IN	B-PP
O	1943	1944	a	a	DT	B-NP
O	1945	1948	new	new	JJ	I-NP
O	1949	1958	treatment	treatment	NN	I-NP
O	1959	1967	modality	modality	NN	I-NP
O	1968	1971	for	for	IN	B-PP
O	1972	1980	ischemic	ischemic	JJ	B-NP
B-Organ	1981	1986	heart	heart	NN	I-NP
O	1987	1994	disease	disease	NN	I-NP
O	1995	1999	with	with	IN	B-PP
O	2000	2002	or	or	CC	B-PP
O	2003	2005	in	in	IN	B-PP
O	2006	2011	place	place	NN	B-NP
O	2012	2014	of	of	IN	B-PP
O	2015	2022	current	current	JJ	B-NP
O	2023	2032	therapies	therapy	NNS	I-NP
O	2032	2033	.	.	.	O

